Bio-Rad Laboratories, Inc. (BIO.B) stock
BIO.BNYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 8/3055% above fair value
$379.50+0.00 (0.00%)
Close on Oct 29, 2026Market cap $10.18BP/E 46.2Yield –
Bio-Rad Laboratories statistics
103 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Q3 FY2026, expected soon
- Last ex-dividend date
- No dividends
- Fundamentals through
- Jun 30, 2026
- Share price as of
- Oct 30, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 1.55
- 4.37
- P/OCF Ratio
- 20.28
- 21.75
Enterprise valuationIndustry
- EV / Sales
- 3.54
- 2.88
- EV / EBIT
- 172.75
- 24.86
- EV / FCF
- 25.98
- 27.38
Share statisticsIndustry
- Shares Change (YoY)
- -3.11%
- 3.50%
- Float
- 12M
- 37M
- Shares Held by Insiders
- 54.5%
- 9.82%
- Shares Held by Institutions
- 83.2%
- 59.9%
Short sellingIndustry
- Short Interest
- 1M
- –
- Short Interest Change
- 18.4%
- 0.63%
- Days to Cover
- 4.27
- 3.83
Stock price statisticsIndustry
- 52-Week High
- $396.23
- –
- 52-Week Low
- $236.73
- –
- 20-Day Moving Average
- $367.43
- –
- 50-Day Moving Average
- $374.80
- –
- 200-Day Moving Average
- $313.41
- –
- Average True Range (14)
- $11.71
- –
- Price Change (1 Week)
- 0.60%
- -1.11%
- Price Change (1 Month)
- 4.67%
- -4.57%
- Price Change (3 Months)
- 11.2%
- -7.22%
- Price Change (6 Months)
- 45.1%
- -5.63%
- Price Change (YTD)
- 22.8%
- -4.10%
- Price Change (1 Year)
- 16.5%
- -6.46%
- Price Change (3 Years)
- 35.2%
- 8.09%
- Price Change (5 Years)
- -53.2%
- -48.0%
- Price Change (10 Years)
- 135.4%
- 60.5%
- Average Volume (10 Days)
- 230,244
- –
- Average Volume (20 Days)
- 225,701
- –
- Average Volume (90 Days)
- 272,795
- –
- Relative Volume
- 0.67
- 0.89
- Relative Strength Index (14)
- 51.6
- 44.9
- Volatility (1 Year)
- 36.6%
- 64.2%
- Beta (5 Years)
- 1.03
- 1.06
MarginsIndustry
- Pretax Margin
- 13.5%
- -2.95%
- EBITDA Margin
- 2.05%
- -2.67%
- FCF Margin
- 13.6%
- 0.06%
Returns on capitalIndustry
- Return on Equity (ROE)
- 3.11%
- -18.2%
- Return on Assets (ROA)
- 2.17%
- -13.0%
- Return on Invested Capital (ROIC)
- 0.51%
- -3.00%
- Return on Capital Employed (ROCE)
- 0.57%
- -9.07%
Financial positionIndustry
- Current Ratio
- 3.14
- 2.49
- Quick Ratio
- 2.14
- 1.53
- Debt / Equity
- 0.11
- 0.38
- Debt / EBITDA
- 15.12
- 2.40
- Debt / FCF
- 2.27
- 3.41
- Net Debt / EBITDA
- -15.36
- 1.48
- Interest Coverage
- 1.09
- -1.85
GrowthIndustry
- Revenue Growth (YoY)
- 1.37%
- 9.06%
- Net Income Growth (YoY)
- -30.3%
- 11.4%
- EPS Growth (YoY)
- -29.7%
- 12.5%
- FCF Growth (YoY)
- -4.82%
- 6.80%
- Revenue Growth (3Y CAGR)
- -2.68%
- 7.08%
- Revenue Growth (5Y CAGR)
- 0.29%
- 11.8%
- EPS Growth (5Y CAGR)
- -26.1%
- 7.64%
EfficiencyIndustry
- Asset Turnover
- 0.25
- 0.58
- Inventory Turnover
- 1.58
- 2.22
- Revenue Per Employee
- $347.56K
- $324.29K
- Profits Per Employee
- $29.85K
- -$51.88K
- Employee Count
- 7,450
- 185
- WACC
- 9.67%
- 9.89%
Income statement (TTM)Industry
- Pretax Income
- $350.40M
- -$2.37M
Balance sheetIndustry
- Net Cash (Debt)
- $815.50M
- $3.92M
- Net Cash Per Share
- $30.50
- $0.28
- Equity (Book Value)
- $7.17B
- $55.33M
- Book Value Per Share
- $268.30
- $2.90
- Tangible Book Value
- $6.44B
- $10.79M
- Working Capital
- $2.06B
- $56.72M
Cash flow (TTM)Industry
- Capital Expenditures
- -$139.50M
- -$3.69M
- FCF Per Share
- $13.21
- -$0.02
Dividends and yieldsIndustry
- Earnings Yield
- 2.23%
- -5.33%
- FCF Yield
- 3.54%
- -0.06%
- Buyback Yield
- 1.33%
- 0.79%
- Shareholder Yield
- 1.33%
- 0.88%
Taxes and interestIndustry
- Interest Expense
- $48.80M
- $5.22M
- Income Tax
- $128.00M
- $1.58M
- Effective Tax Rate
- 36.5%
- 18.4%
Scores and fair valueIndustry
- Graham Number
- $223.17
- $35.47
- Graham Upside
- -40.3%
- -60.0%
- Altman Z-Score
- 3.55
- 2.40
- Piotroski F-Score
- 6
- 5
- Beneish M-Score
- -2.29
- -2.64
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 29, 2026. The S&P 500 is measured by the SPY fund.
| Period | BIO.B | S&P 500 | Difference | BIO.B per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +3.9% | +0.7% | +3.3 pts | ||
| 3 months | +22.7% | +5.7% | +16.9 pts | ||
| Year to date | +22.1% | +13.7% | +8.4 pts | ||
| 1 year | +18.2% | +13.1% | +5.0 pts | ||
| 3 years | +40.0% | +94.3% | −54.2 pts | +11.9% | +24.8% |
| 5 years | -48.0% | +79.1% | −127.1 pts | -12.3% | +12.4% |
| 10 years | +132.8% | +323.9% | −191.0 pts | +8.8% | +15.5% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Sep 30, 2026.
0M BIO.B shares were sold short on Sep 30, 2026. At recent volumes it would take 1.0 days to buy them back. Over the last 20 sessions, 68.6% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Sep 30, 2026 | 1 | – | 20 | 1.0 |
| Aug 14, 2026 | 2 | 0.0% | 17 | 1.0 |
| Jul 31, 2026 | 2 | -93.5% | 12 | 1.0 |
| Jul 15, 2026 | 31 | -85.9% | 102 | 1.0 |
| Jun 30, 2026 | 220 | +21900.0% | 106 | 2.1 |
| Jun 15, 2026 | 1 | -98.9% | 17 | 1.0 |
| May 29, 2026 | 91 | +97.8% | 27 | 3.4 |
| May 15, 2026 | 46 | +35.3% | 490 | 1.0 |
| Apr 30, 2026 | 34 | +17.2% | 71 | 1.0 |
| Apr 15, 2026 | 29 | +11.5% | 17 | 1.7 |
| Mar 31, 2026 | 26 | -23.5% | 20 | 1.3 |
| Mar 13, 2026 | 34 | +142.9% | 51 | 1.0 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.